DE1926011A1 - Pharmazeutisches Praeparat mit antagonistischer Wirkung - Google Patents
Pharmazeutisches Praeparat mit antagonistischer WirkungInfo
- Publication number
- DE1926011A1 DE1926011A1 DE19691926011 DE1926011A DE1926011A1 DE 1926011 A1 DE1926011 A1 DE 1926011A1 DE 19691926011 DE19691926011 DE 19691926011 DE 1926011 A DE1926011 A DE 1926011A DE 1926011 A1 DE1926011 A1 DE 1926011A1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical preparation
- antagonistic effect
- effect
- antagonistic
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 2
- 230000003042 antagnostic effect Effects 0.000 title description 5
- 230000000948 sympatholitic effect Effects 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19681768033 DE1768033A1 (de) | 1967-03-31 | 1968-03-22 | Pharmazeutische Praeparate mit antagonistischer Wirkung gegenueber Adrenalin |
| FR162424A FR332F (en)) | 1968-08-08 | 1968-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1926011A1 true DE1926011A1 (de) | 1971-02-11 |
Family
ID=8653627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691926011 Pending DE1926011A1 (de) | 1968-03-22 | 1969-05-21 | Pharmazeutisches Praeparat mit antagonistischer Wirkung |
Country Status (5)
| Country | Link |
|---|---|
| BE (1) | BE723147A (en)) |
| DE (1) | DE1926011A1 (en)) |
| FR (1) | FR332F (en)) |
| GB (1) | GB1251237A (en)) |
| LU (1) | LU57221A1 (en)) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1209160B (it) | 1979-12-20 | 1989-07-10 | Blasinachim Spa | Processo per la sintesi di 4-[2-(dimetilammino)-etossi]2-metil-5-81-metiletil)-fenol-este ri |
-
1968
- 1968-08-08 FR FR162424A patent/FR332F/fr not_active Expired
- 1968-10-30 BE BE723147A patent/BE723147A/xx unknown
- 1968-10-31 LU LU57221A patent/LU57221A1/xx unknown
- 1968-12-09 GB GB5845468A patent/GB1251237A/en not_active Expired
-
1969
- 1969-05-21 DE DE19691926011 patent/DE1926011A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR332F (en)) | 1970-10-19 |
| GB1251237A (en)) | 1971-10-27 |
| BE723147A (en)) | 1969-04-01 |
| LU57221A1 (en)) | 1969-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Doenicke et al. | HISTAMINE RELEASE AFTER INTRAVENOUS APPLICATION OF SHORT-ACTING HYPNOTICS: A Comparison of Etomidate, Aithesin (CT1341) and Propanidid | |
| DE2934718A1 (de) | Loesung fuer die intravenoese verabreichung | |
| DE69735162T2 (de) | L-carnosin enthaltende mittel zur behandlung von nierenversagen | |
| DE2326600C2 (en)) | ||
| DE2824165A1 (de) | Arzneimittel mit angstneurosen und angstaehnliche neurosen beseitigender wirkung und verfahren zum zubereiten des arzneimittels | |
| DE69430427T2 (de) | Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade | |
| DE69529819T2 (de) | Neue kombination eines betablockers mit einem lokalanästhetikum | |
| DE1926011A1 (de) | Pharmazeutisches Praeparat mit antagonistischer Wirkung | |
| EP0132595B1 (de) | Tokolytisches Mittel | |
| DE1917283B2 (de) | Herstellung antimikrobieller Präparate | |
| DE2528460A1 (de) | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans | |
| DE3781045T2 (de) | Antirheumatisches arzneimittel. | |
| DE2145357C2 (de) | Arzneimittelzubereitung, enthaltend Natrium-Dantrolen | |
| DE2820899C2 (en)) | ||
| DE4000775A1 (de) | Cimetidin/pirenzepin-kombinationspraeparate zur behandlung von peptischen ulzera und erosionen | |
| DE2753140C2 (de) | Arzneimittel zur Behandlung von Magengeschwüren | |
| DE1617336C2 (de) | Arzneimittel gegen Angina pectoris | |
| DE2352618B2 (de) | Peroral oder rektal verabreichbares arzneimittel zur behandlung des parkinsonismus | |
| DE2004281C3 (de) | Vasodilatatorisches Mittel | |
| DE3023396C2 (de) | Arzneimittel zur intravenösen Krebstherapie | |
| DE1692039A1 (de) | Neue Verwendungsarten des Alkaloids Raubasin sowie entsprechende Zubereitungen | |
| DE1806400A1 (de) | Pharmazeutisches Produkt,insbesondere injizierbares Lakalanaesthetikum | |
| DE1197193B (de) | Verfahren zur Herstellung von injizierbaren waessrigen Loesungen der Acetylsalicylsaeure | |
| DE2144060C3 (de) | Arzneimittel mit antikonvulsiver Wirkung | |
| DE1617806C (de) | Verfahren zur Herstellung eines Heil mittels gegen allergische Beschwerden |